As the life sciences sector grapples with a rapidly changing environment and increasing regulatory scrutiny, Frits Stulp of Iperion – a Deloitte business, predicts that by harnessing the power of digital transformation, companies will reduce process burdens to focus on delivering optimum patient outcomes.
Key insights:
- The aim of the EU clinical trial portal is to harmonise and streamline processes across the diverse region, making it a less daunting location for conducting clinical trials.
- The increased speed of regulatory processes seen during the pandemic has set a precedent, and the only way to maintain that pace over the longer term is to modernise.
- From operational efficiency to more convenient and affordable routine patient care, the unifying enabler is good quality, standards-based data that everyone can trust.
Last year was another challenging one for the life sciences industry. On top of residual pandemic-related challenges and supply chain issues, the ever-adapting regulatory environment has continued to set new standards and enforce new requirements. Those companies that have managed to keep pace with the changes can expect to start reaping some of the rewards of their efforts over the coming year. Others still have work to do, but as new waves of digital transformation promise new process efficiency burdens should start to reduce and improved patient experiences will gradually become a reality.